TGFB1 and cancer: A phase I/II clinical trial in patients with pancreatic cancer is underway to convert CAFs to cancer-restraining NFs on the basis of inhibiting meflin, which, as noted above, is an inhibitor of TGFβ signaling, mediated by BMP-7 binding, to induce stromal softening by preventing collagen crosslinking and fibrosis in combination with two chemotherapy agents [575].